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Rhein is a major medicinal ingredient isolated from several traditional Chinese medicines,
including Rheum palmatum L., Aloe barbadensis Miller, Cassia angustifolia Vahl.,
and Polygonum multiflorum Thunb. Rhein has various pharmacological activities,
such as anti-inflammatory, antitumor, antioxidant, antifibrosis, hepatoprotective, and
nephroprotective activities. Although more than 100 articles in PubMed are involved in
the pharmacological mechanism of action of rhein, only a few focus on the relationship
of crosstalk among multiple pharmacological mechanisms. The mechanism of rhein
involvesmultiple pathwayswhich contain close interactions. From the overall perspective,
the pathways which are related to the targets of rhein, are initiated by the membrane
receptor. Then, MAPK and PI3K-AKT parallel signaling pathways are activated, and
several downstream pathways are affected, thereby eventually regulating cell cycle and
apoptosis. The therapeutic effect of rhein, as amultitarget molecule, is the synergistic and
comprehensive result of the involvement of multiple pathways rather than the blocking or
activation of a single signaling pathway. We review the pharmacological mechanisms of
action of rhein by consulting literature published in the last 100 years in PubMed. We then
summarize these pharmacological mechanisms from a comprehensive, interactive, and
crosstalk perspective. In general, the molecular mechanism of action of drug must be
understood from a systematic and holistic perspective, which can provide a theoretical
basis for precise treatment and rational drug use.
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INTRODUCTION
Rhein (Figure 1), a lipophilic anthraquinone, is an active ingredient mainly extracted and separated
from several traditional rhizomes of medicinal plants, including Rheum palmatum L., Aloe
barbadensis Miller, Cassia angustifolia Vahl., and Polygonum multiflorum Thunb.; rhein also has
a relatively high content in R. palmatum L. (Nawa et al., 1961; Ge et al., 2015). R. palmatum L.,
A. barbadensis Miller, C. angustifolia Vahl., and P. multiflorum Thunb. have been widely used
clinically for thousands of years, and they are an important part of various Chinese medicinal
formulae, such as Dahuang Fuzi, Dachengqi, Heshouwu, and Yinchenhao decoction (Wang et al.,
2011; Gong et al., 2012; Niu et al., 2012; Li et al., 2013). Rhein is considered the major active
ingredient of these aforementioned Chinese medicinal formulae (Peng et al., 2014; Li et al., 2015).
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FIGURE 1 | Chemical structure of rhein.
Modern pharmacological studies indicated that rhein can
exert a significant therapeutic anti-inflammatory, antitumor,
antioxidant, antifibrosis, hepatoprotective, and nephroprotective
effects (Zhou Y. X. et al., 2015). Till date, more than 1000 articles
about rhein can be found in PubMed, andmore than 100 of which
have paid attention on its pharmacological mechanism of action.
At present, only a few articles pay attention to the relationship on
the crosstalk among multiple pharmacological mechanisms. For
example, rhein can significantly block ERK1/2 pathway activation
(Zhu et al., 2003) and can inhibit AKT phosphorylation
(Fernand et al., 2011). However, the activated AKT can inhibit
Raf by the phosphorylation, thereby indirectly suppressing
ERK1/2 pathway (Ersahin et al., 2015). The inhibition of AKT
phosphorylation by rhein indicates that the AKT on ERK1/2
pathway inhibition is removed. Rhein regulation on the signaling
pathways is the comprehensive result of the crosstalk signaling
networks. Therefore, the molecular mechanism of action of drug
must be understood from a systematic and holistic perspective,
which can provide a theoretical basis for precision treatment and
rational drug use.
In this review, we review the pharmacological mechanisms
of action of rhein by consulting the literature published in the
last 100 years, and these pharmacological mechanisms of action
are summarized from a comprehensive, interactive, and crosstalk
perspective, which can provide a valuable reference for further
utilization and development of rhein. All pharmacological
mechanisms of rhein are summarized in Table 1.
RHEIN REGULATION ON SIGNAL
TRANSDUCTION
MAPK Signaling Pathway
MAPK is a hub molecule of signal transduction, which is the
center of various signaling pathways. MAPK can be grouped
into four main families, including ERK1/2, JNK, p38 MAPK,
and ERK5. ERK is mainly involved in the regulation of cell
proliferation and differentiation, whereas JNK and p38 MAPK
are mainly responsible for the transduction of the signal
induced by stress, thereby mediating inflammation and apoptosis
(Morrison, 2012). Rhein can regulate multiple sites of MAPK
signaling pathways, and its targets are mainly involved in three
signaling cascades, including ERK1/2, JNK, and p38 MAPK.
Rhein can regulate GRB2/SOS-Ras-MAPK pathway, as shown by
downregulating the expression levels of GRB2, SOS-1, and Ras,
thereby resulting in the inhibition of ERK1/2 and p38 MAPK
phosphorylation (Lin et al., 2009). RTKs and their ligands, as
upstream regulators of GRB2/SOS-Ras-MAPK pathway, are also
regulated by rhein (Fernand et al., 2011; He Z. H. et al., 2011;
Su et al., 2013). Rhein can also inhibit JNK phosphorylation
(Lin et al., 2003b; Legendre et al., 2007), whereas the multiple
membrane receptors of JNK signaling cascade, such as Fas and
TGFBR1, and the multiple signal molecules, such as Fas-L, TGF-
β, TNF-α, and IL-1β, are regulated by rhein (Kuo et al., 2004; Ip
et al., 2007; Heo et al., 2010; He D. Y. et al., 2011; Gao et al.,
2014; Meng et al., 2015; Yu et al., 2015). Although most of the
literature reported that rhein has inhibitory effects on MAPK
phosphorylation, a few studies had the opposite conclusion. It
is observed that a rapid phosphorylation of p38 is determined
after 0.5 h when HL-60 cell was treated with 100 µM of rhein,
whereas JNK phosphorylation occurs after 6–8 h (Lin et al.,
2003a). Similarly, 10 µg/mL rhein significantly increases cell
proliferation and ERK phosphorylation (Aviello et al., 2010).
As a matter of fact, MAPK signaling pathway is regulated
by rhein in a dose-dependent manner. With small doses, rhein
often plays a role in blocking the MAPK signaling pathway,
while an antagonistic effect occurs at high doses. When this
pathway is blocked, biological processes are usually negative
at the cellular level. Thus, cells are typically characterized by
reducing proliferation and secretion of inflammatory mediators.
The mediation mechanism partly explains why the rhein, with
small doses, shows antitumor effects and anti-inflammatory
activities (Martin et al., 2003). On the contrary, high doses rhein
usually shows a significant toxicity which was demonstrated to
increase cell proliferation (Aviello et al., 2010).
PI3K-AKT Signaling Pathway
PI3K-AKT signaling pathway widely exists in many kinds of
cells, thereby regulating various cellular functions, including cell
proliferation, differentiation, apoptosis, and glucose transport
(Morgan et al., 2009). PI3K is an important molecule for
extracellular signal transduction, and its activation is controlled
by different kinds of membrane receptors and Ras protein.
Various growth factors, cytokines, chemokines, extracellular
matrix, or other signals activate their corresponding receptors.
Then, these receptors phosphorylate themselves and activate
PI3K (Hevner, 2015). PI3K activation converts PIP2 to
PIP3. PIP3, a second messenger, promotes AKT protein
phosphorylation through PKD1 (Morgan et al., 2009). The
activated AKT regulates its downstream multiple proteins to
exert various cellular functions. Rhein mainly regulates the two
key proteins, namely, PI3K and AKT, to influence this signaling
pathway. The majority of researchers agreed that rhein can
inhibit the activation of PI3K and p-AKT, but it does not
have an inhibitory effect on the total AKT (Fernand et al.,
2011; Cong et al., 2012a; Tsang and Bian, 2015; Wang et al.,
2015). However, rhein treatment to hepatocytes results in the
increase of p-AKT1 or PKC (Panigrahi et al., 2015). In addition,
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TABLE 1 | List of the pharmacological mechanism of rhein.
Pathway Mechanism References
MAPK signaling pathway Inhibiting the phosphorylation of ERK. Martin et al., 2003, 2004; Zhu et al., 2003; Legendre et al., 2007; Lin et al.,
2009; Aviello et al., 2010; Fernand et al., 2011
Inhibiting the phosphorylation of p38 MAPK. Lin et al., 2009; Heo et al., 2010; Hu et al., 2013
Inhibiting the phosphorylation of JNK. Lin et al., 2003b; Legendre et al., 2007
Increasing the phosphorylation of ERK. Aviello et al., 2010; Panigrahi et al., 2015
Increasing the phosphorylation of p38 MAPK. Lin et al., 2003a; Panigrahi et al., 2015
Increasing the phosphorylation of JNK. Lin et al., 2003a; Panigrahi et al., 2015
Reducing the expression of GRB2, SOS-1 and Ras. Lin et al., 2009
Regulating membrane receptors and their ligands. Kuo et al., 2004; Ip et al., 2007; Heo et al., 2010; Fernand et al., 2011; He
D. Y. et al., 2011; He Z. H. et al., 2011; Su et al., 2013; Gao et al., 2014;
Meng et al., 2015; Yu et al., 2015
PI3K-AKT signaling pathway Inhibiting the phosphorylation of PI3K. Fernand et al., 2011
Inhibiting the phosphorylation of AKT. Fernand et al., 2011; Cong et al., 2012a; Tsang and Bian, 2015; Wang
et al., 2015
Increasing the phosphorylation of AKT and PKC. Panigrahi et al., 2015
Regulating extracellular signal. Guo et al., 2001; Gao et al., 2010; Su et al., 2013
TGF-β signaling pathway Inhibiting the expression of TGF-β and its type I receptor. Guo et al., 2002; Zhu et al., 2003; Zheng et al., 2008; Gao et al., 2010; He
D. Y. et al., 2011; Meng et al., 2015; Tsang and Bian, 2015
Inhibiting the effect of TGF-β on upregulating the
expression of GLUT1 and stimulating the glucose
uptake.
Zhang et al., 1999; Liu et al., 2001; Zheng et al., 2008
Increasing the levels of BMP7. Su et al., 2013
Regulating the expression of ECM and α-SMA Martin et al., 2003, 2004; Sanchez et al., 2003; Peng et al., 2013; Tsang
et al., 2013; Tsang and Bian, 2015
Wnt signaling pathway Increasing the expression of β-catenin, inhibiting DKK1
and DKK2.
Martel-Pelletier et al., 2011
VEGF signaling pathway Inhibiting the expression of VEGF. Lin et al., 2009; Fernand et al., 2011; He Z. H. et al., 2011
Inhibiting the expression of KDR. He Z. H. et al., 2011
Inhibiting Hsp90α activity to induce degradation of
COX-2.
Fernand et al., 2011
NF-κB signaling pathway Inhibiting the activation or expression of NF-κB. Lin et al., 2009; Fernand et al., 2011; Ge et al., 2011; Gao et al., 2014;
Tsang and Bian, 2015; Yu et al., 2015
Inhibiting the binding of NF-κB and AP-1. Martin et al., 2003, 2004; Legendre et al., 2007
Inhibiting the phosphorylation or expression of IκB. Fernand et al., 2011; Yu et al., 2015
Inhibiting the activation or expression of IKK. Gao et al., 2014; Yu et al., 2015
HIF-1 signaling pathway Inhibiting the expression of HIF-1α. Fernand et al., 2011
AMPK signaling pathway Increasing levels of AMPK and p-AMPK. Panigrahi et al., 2015
Inhibiting the expression and transcriptional activity of
SREBP-1c.
Sheng et al., 2011
Increasing the activity of CFTR. Shi et al., 2006
FOXO signaling pathway Increasing the activity of FOXO, upregulating the
expression of Bim.
Wang et al., 2015
Cell Cycle Regulating Cyclins. Hsia et al., 2009; Lai et al., 2009
Regulating CDKs. Hsia et al., 2009
Regulating CKIs. Kuo et al., 2004; Ip et al., 2007; Zheng et al., 2008; Hsia et al., 2009; Lai
et al., 2009; Legendre et al., 2009; Panigrahi et al., 2015
(Continued)
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TABLE 1 | Continued
Pathway Mechanism References
Apoptosis Regulating TNF receptor family and its ligands. Kuo et al., 2004; Ip et al., 2007; Deffaud et al., 2008; Heo et al., 2009,
2010; Lai et al., 2009; Gao et al., 2014; Meng et al., 2015; Yu et al., 2015
Inducing MOMP, releasing CytC. Bironaite and Ollinger, 1997; Lin et al., 2003a, 2007; Ip et al., 2007; Heo
et al., 2009; Hsia et al., 2009; Lai et al., 2009; Li et al., 2012; Du et al.,
2013; Zhao et al., 2014; Bounda et al., 2015; Panigrahi et al., 2015
Regulating Caspase family. Lin et al., 2003a; Ip et al., 2007; Lin et al., 2007; Shi et al., 2008; Heo et al.,
2009; Lai et al., 2009; Legendre et al., 2009; Ge et al., 2011; Chang et al.,
2012; Li et al., 2012; Zhong et al., 2012; Du et al., 2013; Gao et al., 2014;
Zhao et al., 2014; Bounda et al., 2015; Panigrahi et al., 2015; Wang et al.,
2015
Regulating pro-apoptotic or pro-survival protein. Lin et al., 2003a; Ip et al., 2007; Lin et al., 2007; Chipuk and Green, 2009;
Gallenne et al., 2009; Heo et al., 2009; Hsia et al., 2009; Lai et al., 2009; Ge
et al., 2011; Li et al., 2012; Reubold and Eschenburg, 2012; Wen et al.,
2012; Zhao et al., 2014; Bounda et al., 2015; Cheng et al., 2015; Panigrahi
et al., 2015
p53 signaling pathway Increasing the expression of p53. Kuo et al., 2004; Ip et al., 2007; Hsia et al., 2009; Zhao et al., 2014;
Panigrahi et al., 2015
Inhibiting p53. Lai et al., 2009
Protein processing in
endoplasmic reticulum
Regulating the expression of Bip. Lin et al., 2007; Hsia et al., 2009; Lai et al., 2009; Wang et al., 2015
Regulating the expression of CHOP. Lin et al., 2007; Hsia et al., 2009; Lai et al., 2009; Wang et al., 2015
Regulating ATF6, PERK, eIF2α and XBP1. Lin et al., 2007; Cong et al., 2012a,b; Wang et al., 2015
PPAR signaling pathway Inhibiting the expression and transcription of PPARγ. Liu et al., 2011; Zhang et al., 2012
Inhibiting the expression of PPARα. Hu et al., 2011
several extracellular signals for this signaling pathway can also
be influenced by rhein. For instance, rhein can notably increase
the HGF level (Su et al., 2013) and decrease the ECM level
(Guo et al., 2001; Gao et al., 2010) in the kidney tissues. The
activation of PI3K-AKT signaling pathway always inhibits pro-
apoptotic protein and promotes pro-survival protein (Datta et al.,
1997; Cardone et al., 1998; Engelman et al., 2006). With a
suitable dose, rhein always inhibits the activation of this pathway.
This may be another reason for its antitumor activity, but not
all of it.
TGF-β Signaling Pathway
TGF-β family members, including TGF-βs, activins, and BMPs,
are a multifunctional cytokine. They regulate the proliferation,
differentiation, death, and migration of various cells (Moustakas
et al., 2002) and influence angiogenesis, extracellular matrix
regeneration, and immune suppression (Derynck and Zhang,
2003). TGF-β family member phosphorylates R-Smads through
binding to the Type II receptor and recruiting Type I.
Phosphorylated R-Smads combine with Smad4, and then this
complex translocates into the nucleus to regulate target gene
transcription (Shi and Massagué, 2003).
In many fibrosis diseases, TGF-β signaling pathway has
attracted much attention. Many fibrosis-related proteins, such
as ECM and α-SMA, have been expressed due to the activation
of this pathway. The imbalance of ECM and overexpression of
α-SMA accelerate the progression of fibrosis. Rhein can reduce
FN deposition and α-SMA expression to exert its anti-fibrosis
activity (Peng et al., 2013; Tsang et al., 2013; Tsang and
Bian, 2015). On the contrary, some ECM components, such
as COL2A1 and ACAN, are elevated by rhein (Martin et al.,
2003, 2004; Sanchez et al., 2003). Moreover, rhein can inhibit
the expression of TGF-β and its type I receptor (Guo et al.,
2002; He D. Y. et al., 2011), antagonize the expression of
GLUT1 which would be upregulated by TGF-β1, and stimulate
the ability of glucose uptake in mesangial cells (Zhang et al.,
1999; Liu et al., 2001; Zheng et al., 2008). In addition, rhein
can also improve renal function and reduce renal fibrosis and
interstitial inflammation by increasing the level of BMP7 (Su
et al., 2013).
Wnt Signaling Pathway
In the canonical Wnt pathway, β-catenin is a vital
multifunctional protein involved in cell proliferation,
differentiation, and apoptosis (Hatsell et al., 2003). The
classical Wnt signal is delivered to the cytoplasm, and it
eventually stabilizes the cytoplasmic β-catenin and makes
β-catenin continuous accumulation. Subsequently, β-catenin
transfers to the nucleus to regulate the expression of target
genes (Nusse, 2005). Rhein significantly elevates the expression
level of β-catenin and inhibits the Wnt antagonists DKK-1
and DKK-2 in a dose-dependent manner. This result indicates
that rhein has a positive impact on osteoarthritis subchondral
bone osteoblasts (Martel-Pelletier et al., 2011). It implies that
the chondroprotective activity of rhein partly attributes to the
regulation on this pathway.
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VEGF Signaling Pathway
VEGFR-2, known as KDR, is the major mediator of VEGF-
driven responses in endothelial cells, and it is considered a vital
signal sensor in both physiologic and pathologic angiogenesis
(Cross et al., 2003). Several downstream signaling pathways are
perturbed when VEGF binds to KDR. This phenomenon results
in the upregulation of genes mediating the proliferation and
migration of endothelial cells and promoting their survival and
vascular permeability (Takahashi and Shibuya, 2005). The effect
of rhein on negative regulating VEGF signaling pathway is one
reason for its antitumor and anti-inflammatory activity. 20 µM
rhein can downregulate the expression of VEGFA and receptor
KDR to inhibit angiogenesis and cell migration completely (He
Z. H. et al., 2011). Rhein can also inhibit VEGF effectively
in human nasopharyngeal carcinoma cells and umbilical vein
endothelial cells (Lin et al., 2009; Fernand et al., 2011). In the
downstream of VEGF signaling pathway, rhein inhibits Hsp90α
activity to induce the degradation of its client protein COX-2 and
to promote the production of PGI2 which can inhibit the release
of inflammatory mediators (Fernand et al., 2011).
NF-κB Signaling Pathway
NF-κB signaling pathway involves in immunity, inflammation,
apoptosis, cell survival, stress response, and other biological
processes (Oeckinghaus et al., 2011). As the hub protein in this
pathway, NF-κB plays a key role to regulate the gene expression
induced by cytokine. Various signals initially phosphorylate
IKK, and further phosphorylate IκBs. Phosphorylated IκBs are
degraded by protease through ubiquitination, which activate
NF-κB. The activated NF-κB subsequently enters the nucleus
to combine with DNA (Perkins, 2007). IL-1β induces the
degradation of IκB protein and the translocation of RELA to
the nucleus; these activities are dose-dependently suppressed
by rhein (Mendes et al., 2002). The binding of both NF-κB
and AP-1 transcription factors can also be effectively inhibited
by rhein (Martin et al., 2003, 2004; Legendre et al., 2007).
As discussed under “VEGF Signaling Pathway”, rhein inhibits
Hsp90α activity to induce the degradation of client protein
NF-κB. IκB phosphorylation can be inhibited by rhein under
normoxic or hypoxic conditions (Fernand et al., 2011). In LPS-
activated macrophages, rhein inhibits NF-κB activation and
sequentially suppresses the transcription of several downstream
genes and inhibits NO and IL-6 levels by inhibiting IKKβ (IC50
≈ 11.79 µM). Rhein also elevates the activity of Caspase-1 by
inhibiting intracellular IKKβ, thereby increasing the release of IL-
1β and HMGB1. Rhein significantly increases TNF-α secretion
and the phagocytosis of macrophages with or without LPS
because of IKKβ inhibition (Gao et al., 2014). In general, rhein
can inhibit the activation of IκB, IKK, and NF-κB (Lin et al.,
2009; Ge et al., 2011; Yu et al., 2015). Rhein exerts its antitumor
and anti-inflammatory activity through the downregulation of
the pathway.
HIF-1 Signaling Pathway
HIF-1α, which is a key regulator of oxygen balance, plays essential
roles in the angiogenesis of tumors andmammalian development
(Lee et al., 2004). HIF-1α is degraded under normoxia. HIF-1α
is stable only under hypoxia, and it interacts with coactivators
to induce the activation of hypoxia target genes by regulating
its transcriptional activity (Semenza, 2010). Rhein is a potential
HIF-1α activity inhibitor in hypoxia-induced tumor angiogenesis
of breast cancer cells. Rhein dose-dependently and significantly
suppresses CoCl2-stabilized HIF-1α expression in MCF-7 and
MDA-MB-435s cells (Fernand et al., 2011). The downregulation
of the pathway is not the most important, but is essential
condition for the antitumor activity of rhein.
AMPK Signaling Pathway
AMPK, which is a transducer of cellular energy status, can be
activated by metabolic stresses that disturb energy balance and by
the upstream kinase of AMPK through phosphorylation (Hardie,
2004). The activated AMPK switches on the catabolic pathways
to generate ATP, whereas it switches off the ATP-consuming
processes, such as biosynthesis, cell growth, and proliferation
(Towler and Hardie, 2007).
Compared with the controls, AMPK and p-AMPK in the
treatment group with 50 µM rhein are increased to an extent
of 2.3- and 1.6-fold in hepatocytes, respectively. AMPK can
activate p53 to induce apoptosis, suggesting that rhein can
lead to liver toxicity (Panigrahi et al., 2015). AMPK also
can inhibit the lipogenic enzyme SREBP-1c indirectly. Gene
analysis and Western blot analysis showed that rhein obviously
inhibits the expression of SREBP-1c and its target genes in the
liver. Luciferase reporter assay revealed that rhein suppresses
the transcriptional activity of SREBP-1c through its upstream
regulator LXR. These results indicate that rhein can improve
nonalcoholic fatty liver disease and associated disorders through
LXR-mediated negative energy balance (Sheng et al., 2011).
It is interesting that, rhein regulation on the pathway shows
two opposite results, liver toxicity and protection. In fact, this
situation results from two parallel and independent mechanisms
of AMPK downstream. However, mediation mechanisms,
playing a dominant role, depends on many factors because of the
complexity of biological networks. In addition, 5 µM rhein can
significantly activate the downstream protein CFTR of AMPK
signaling pathway, and the full activation was detected at 20
µM, thereby promoting CL− secretion (Shi et al., 2006). Maybe
the purgative activity of rhein is traceable to this regulatory
mechanism.
FOXO Signaling Pathway
FOXO regulates the expression of genes in cellular physiological
events, such as cell metabolism, differentiation, cycle arrest,
DNA repair, and other reactions to cellular stress (Glauser and
Schlegel, 2007). FOXO activation is regulated through several
posttranslational modifications, including phosphorylation,
acetylation, methylation, and ubiquitylation (van der Horst and
Burgering, 2007). Researchers transfected FOXO-responsive
luciferase construct and Renilla luciferase reporter plasmid
(pRL-TK) into MCF7 and HepG2 cells. Then, the cells were
treated with or without 100 µM rhein for 24 h, and the dual
luciferase activity was detected. The experiments determined
that rhein can enhance the activity of FOXO in MCF7 and
HepG2 cells. In addition, the expression of FOXO3-mediated
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Bim is induced and upregulated by rhein (Wang et al., 2015). The
upregulation of the pathway is a key mechanism of the potential
rhein-induced cancer cells apoptosis.
RHEIN REGULATION ON CELLULAR
PROCESSES
Cell Cycle
In general, mitosis can be roughly divided into two stages,
including interphase and mitotic stage. In cell cycle, cyclins
and CDKs are the two key regulatory molecules determining a
cell progress, and none of these two molecules has a catalytic
activity (Nigg, 1995). These two molecules can exert kinase
activity only when they form cyclin–CDK complex. In each
phase, the corresponding cyclins regulate the cell cycle. For
example, cyclin D1 and cyclin E regulate G1 phase to S phase;
cyclin A regulate S phase to G2 phase; and cyclin B regulate
G2 phase to M phase. Different cyclin–CDK combinations have
different biological functions. CDK4/6 associated with cyclin D
controls cell growth of G1 phase. CDK2 combined with cyclin
A or cyclin E is responsible for chromosome duplication. CDK1
binds to cyclin A or cyclin B to regulate mitosis and meiosis (Lim
and Kaldis, 2013). Cyclin-CDK inhibitors, such as p15Ink4b,
p16Ink4a, p21Cip1, and p27Kip1, are involved in the negative
regulation of CDK activity (Okamoto et al., 1995; Levkau et al.,
1998; Sherr and Roberts, 1999).
Rhein induces G0/G1 arrest through the inhibition of cyclin
D3, CDK4, and CDK6 and increases the levels of p21 and
p53 in A-549 cells (Hsia et al., 2009). Rhein induces S-phase
arrest through the inhibition of p53, cyclin A, and E in SCC-
4 cells. Immunoblot analysis demonstrated that 30 µM rhein
promotes the levels of p21, p27, and Chk2 but reduces the levels
of cyclin B1, cyclin A, Cdc25A, and thymidylate synthase, thereby
eventually leading to S phase arrest (Lai et al., 2009). Likewise,
some articles also reported that rhein increases the expression
levels of p21 and p27, but no effect is detected on cyclin D1
(Kuo et al., 2004; Ip et al., 2007; Legendre et al., 2009; Panigrahi
et al., 2015). However, a decrease of p21 expression is found by
exposing MCGT1 cells to 25 µg/mL rhein for 48 h. This effect of
rhein contributes to the reversion of the diabetic phenotype of the
cells (Zheng et al., 2008). As we know, p21 is a cell cycle inhibitor.
The level of p21 is regulated by rhein in a positive or negative
manner. On the one hand, rhein promotes the expression of
p53-induced p21; on the other hand, rhein can also inhibit TGF-
β-induced p21 expression. Perhaps rhein regulation on the p21
expression in the pathway is a dynamic balance between the two
mediation mechanisms of p21 expression.
Cell Apoptosis
Cell apoptosis is an autonomic ordered programmed cell death
to maintain homeostasis, which is controlled by serial genes.
The onset of apoptosis is controlled by numerous interrelating
processes, including the receptor-mediated extrinsic pathway,
the mitochondrial-mediated intrinsic pathway, and the cytotoxic
granule component-mediated pathway (Cullen et al., 2010;
Schleich and Lavrik, 2013). The extrinsic pathway is mainly
mediated by the TNF receptor family members, such as TNFR1
and Fas (Lavrik et al., 2005). The intrinsic pathway is primarily
activated by nonreceptor stimuli, such as DNA damage, ER stress,
metabolic stress, UV radiation, or growth factor deprivation. The
main process in the intrinsic pathway is MOMP, which results in
CytC release (Jeong and Seol, 2008). However, the final activation
of the effector Caspases, such as Caspase-3 and Caspase-7,
result in apoptosis whether in extrinsic pathway or in intrinsic
pathway.
Rhein, as a potential anticancer agent, can act on multiple
protein targets in apoptosis process. In extrinsic pathway, the
levels of Fas and its ligand are enhanced by the induced apoptosis
effect of rhein (Kuo et al., 2004; Ip et al., 2007). The specific ELISA
experiment demonstrated that rhein can increase the production
of sTNFR I and sTNFR II (Deffaud et al., 2008). Some studies
reported that the expression of ligand TNF-α is inhibited by rhein
(Heo et al., 2010; Meng et al., 2015; Yu et al., 2015). In intrinsic
pathway, rhein induces the loss of mitochondrial membrane
potential, CytC release from mitochondrion to cytosol, and the
cleavage of Bid protein (Lin et al., 2003a). Rhein also reduces
the expression of Bcl-2 and Bcl-XL and increases the expression
of Bax and Bak (Heo et al., 2009). The ratio of Bax/Bcl-2 is
the critical factor that determines whether apoptosis is initiated.
Rhein increases the ratio of Bax/Bcl-2 by reducing the level
of Bcl-2 (Lai et al., 2009; Li et al., 2012; Zhao et al., 2014).
PUMA protein has a powerful proapoptotic function, which can
combine all the antiapoptotic proteins, such as Bcl-2 and Bcl-
XL, and can directly activate Bax (Chipuk and Green, 2009;
Gallenne et al., 2009). Apaf-1 is the real core of apoptosome,
which is combined with CytC, ATP/dATP, and procaspase-9 to
form apoptotic activation complex, thereby activating Caspase-
9 (Reubold and Eschenburg, 2012). 50 and 100 µM rhein with
respective treatment to HL-7702 cells for 12 h can improve the
activity of PUMA and Apaf-1 (Bounda et al., 2015). The release
of AIF and ENDO-G from mitochondria to the cytoplasm leads
to DNA fragmentation (Cheng et al., 2015). Rhein can induce
ENDO-G and AIF release from mitochondria into the cytosol
and the nucleus (Lin et al., 2007; Lai et al., 2009). Caspase
family proteins play an important role in the apoptotic pathway.
Caspase-8 and Caspase-10 can accept extracellular death signal
and then activate their downstream Caspase-3 and Caspase-
7 to induce apoptosis (Stennicke et al., 1998). They can also
initiate intrinsic pathway to cleave Bid protein and then transfer
and locate to mitochondrion (Kim et al., 2000). Moreover,
the activated Caspase-9 and Caspase-12 can activate Caspase-
3 and Caspase-7 from different pathways. Caspase-3 plays an
irreplaceable role in cell apoptosis, and its main substrate is
PARP, which ultimately leads to apoptosis (Wen et al., 2012).
Many studies reported that rhein can activate Caspase-1, -3,
-8, -9, and -12 (Lin et al., 2007; Shi et al., 2008; Chang et al.,
2012; Du et al., 2013; Gao et al., 2014). However, 100 µM
rhein decreases the activity of Caspase-3 and Caspase-7, with
no induction for DNA fragmentation (Legendre et al., 2009).
Rhein can also induce apoptosis through PARP cleavage (Lin
et al., 2003a; Panigrahi et al., 2015). Obviously, the effect of
rhein inducing apoptosis is a synergetic result of the extrinsic
and intrinsic pathway. The two mediation mechanisms are
mutually contributive, rather than mutually replaceable. Thus,
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rhein regulation on apoptosis is relatively stable due to the
robustness and adaptability of biological networks.
p53 Signaling Pathway
p53 protein can be activated by several stress signals, including
DNA damage, oxidative stress, and activated oncogenes. As a
transcription factor, the activated p53 initiates the cell cycle
arrest, cell senescence, and cell apoptosis. The expressed protein
of p53 responsive gene has an influence on many other signaling
pathways in cells (Harris and Levine, 2005). Many articles
reported that rhein significantly increases the expression of p53
(Hsia et al., 2009; Zhao et al., 2014; Panigrahi et al., 2015).
However, it is reported that rhein induces S phase arrest by
inhibiting p53 (Lai et al., 2009). This result is contrary to the
present molecular mechanisms that p53 itself can induce cell
cycle arrest indirectly.
RHEIN REGULATION ON OTHER
SIGNALING PATHWAYS
Protein Processing in Endoplasmic
Reticulum
Endoplasmic reticulum, which is an elaborate membrane system
of cells, is the main place for protein processing. Misfolded
proteins that are bound to Bip are degraded through ERAD
(Stolz and Wolf, 2010). The accumulation of a large number of
misfolded proteins in the ER causes ER stress and activates UPR.
UPR includes three parallel pathways, namely, PERK, ATF6, and
IRE1 pathways. Cells do not induce apoptosis when UPR does
restore the normal function of endoplasmic reticulum (Malhotra
and Kaufman, 2007).
The targets of rhein are involved in the multiple sites of
the three UPR pathways. The results of Western blot analysis
showed that GRP 78 (also known as Bip) expression is enhanced
after rhein treatment in NPC cells. The significant increase in
CHOP protein levels is observed after 12 or 24 h of rhein
treatment (Lin et al., 2007). The results of flow cytometric analysis
also showed that rhein increases the levels of endoplasmic
reticulum stress hallmarks, such as GADD153 (also known as
CHOP) and GRP78 (Hsia et al., 2009). In MCF-7 and HepG2
cells, rhein-induced nonclassical UPR is further investigated.
Rhein induces the expression of CHOP and the phosphorylation
of eIF2α. Rhein also increases the expression of GRP78 and
XBP1 splicing (Wang et al., 2015). As ER stress sensors, ATF6
and PERK are significantly induced after 6 h rhein-treatment.
This result increases the susceptibility to ER stress-induced
apoptosis (Lin et al., 2007). However, the effects of rhein on
ATF-6 are not all positive. Rhein can also significantly inhibit
ATF-6 activation to exert its anti-inflammatory activity (Cong
et al., 2012a,b). In general, rhein can apparently upregulate ER
stress, while the regulation on ATF-6 is controversial. Maybe
the inconsistent regulation is the synthetical result of multiple
upstream pathways.
PPAR Signaling Pathway
PPAR is a nuclear hormone receptor, and it can be activated
by fatty acids and their derivatives. PPAR has three subfamilies,
which are involved in the regulation of the major metabolism,
inflammation, and the important process of controlling cell
fate (Feige et al., 2006). PPARα can regulate the expression of
genes related to lipid metabolism in liver or skeletal muscle
to clear the circulating or cellular lipids. PPARβ/δ is involved
in lipid oxidation and cell proliferation. PPARγ promotes
the differentiation of adipose cells to improve blood glucose
absorption (Desvergne and Wahli, 1999). The effects of rhein
on the differentiation of adipocytes and the lipogenesis were
studied. The result showed that rhein can downregulate the
expression of PPARγ and C/EBPα, which are adipogenesis-
specific transcription factors, and the upstream regulator of these
factors, namely, C/EBPβ, is the same. Moreover, the target genes
of PPARγ involved in adipocyte differentiation are suppressed by
rhein; these target genes include CD36, aP2, acyl CoA oxidase,
uncoupled protein 2, acetyl-CoA carboxylase, and fatty acid
synthase (Liu et al., 2011). Gene expression analysis showed
that as a potential antagonist of PPARγ, rhein inhibits the
transcription of PPARγ and the expression of its target genes.
It indicates that rhein can blocked high-fat diet-induced obesity
(Zhang et al., 2012). In addition, the derivatives of rhein can
significantly alleviate diabetic nephropathy via improving the
expression of PPARα in renal tissue (Hu et al., 2011). These
evidence implies that rhein is an underlying candidate for
preventing metabolic disorders.
RHEIN REGULATION ON THE CROSSTALK
AMONG PATHWAYS
As a multitarget molecule, rhein exerts its therapeutic effect
via multipathways. The pharmacological action of rhein is
the comprehensive regulation result on the crosstalk among
signaling pathways. As shown in Figure 2, the targets of rhein are
involved in a wide range of pathways. Comprehensive crosstalk
exists among these pathways.
Crosstalk of MAPK Signaling Pathway
In the pathways involved in the pharmacological pathways of
rhein, MAPK signaling pathway can be considered one of the
most interactive pathways. The activation of MAPK is affected
by four pathways, including VEGF, TGF-β, Wnt, and PI3K-AKT
signaling pathways. Figure 3 shows that VEGF signaling pathway
starts from the combination of VEGF and its receptor KDR. The
activated KDR induces ERK1/2 phosphorylation by indirectly
activating PLCγ-mediated PKC, rather than by depending on
GRB2/SOS-Ras pathway (Shinya et al., 2015). The activated
KDR can also activate Cdc42 to induce the activation of Cdc42-
SAPK2/p38-MAPKAPK2/3 pathway and to promote stress fiber
formation and endothelial cell migration (Lamalice et al., 2006).
The TGF-β signal indirectly activates p38 MAPK and JNK via
DAXX-TAK1 pathway (Vaidya and Kale, 2015). In the classical
Wnt signaling pathway, Wnt3a can activate Raf-1-MEK-ERK
cascade and JNK pathway (Yun et al., 2005; Bikkavilli et al., 2008).
ERK, p38 MAPK, and JNK are activated by Wnt3a through G
protein mediation (Zhang et al., 2014). PI3K-AKT and MAPK
signaling pathways are two parallel pathways. The interaction of
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FIGURE 2 | The crosstalk among the signaling pathways related to pharmacological mechanism of rhein. The pathways related to rhein are initiated by the
membrane receptors of several pathways. Then, MAPK and PI3K-AKT parallel signaling pathways are activated, and several downstream pathways are affected,
thereby eventually regulating cell cycle and apoptosis. Blue line is the crosstalk of MAPK signaling pathway; Yellow line is the crosstalk of PI3K-AKT signaling pathway;
Purple line is the crosstalk of cell cycle; Green line is the crosstalk of apoptosis; Black line is the crosstalk of other pathways.
PI3K/AKT and Raf/MAPK/ERK1/2 pathways occurs in several
different stages. This interaction can be positive or negative. The
inhibitor of PI3K and AKT eliminates AKT phosphorylation and
restores ERK1/2 phosphorylation. This phenomenon indicates
that Raf/MAPK/ERK1/2 pathway is inhibited by AKT by directly
phosphorylating Raf-1 (Zhou J. et al., 2015). In MCF-7 cells,
AKT can phosphorylate Raf under high IGF-I concentration
conditions. This phenomenon leads to crosstalk generation, Ras-
Raf-MEK-ERK cascade blockage, and proliferation inhibition.
However, the crosstalk of Akt-Raf does not exist under low IGF-I
concentration (Moelling et al., 2002).
The influence of MAPK signaling pathway on other pathways
is extensive and complex. Figure 3 shows that MAPK signaling
pathway can affect the nine pathways related to pharmacological
mechanisms of rhein. The activated TAK1 can activate NLK,
whereas the classical Wnt signaling pathway is silenced through
the degradation and ubiquitylation mediated by β-catenin or
the phosphorylation of TCF/LEF mediated by NLK (Ke et al.,
2016). The activated TAK1 can activate NIK, whereas the classical
NF-κB signaling pathway is activated by NIK, NEMO, and
IKKα (Neely et al., 2011). The activated TAK1 can upregulate
AMPK activity and can regulate energy metabolism (Inokuchi-
Shimizu et al., 2014). The activated ERK can regulate TGF-β
signal by activating Smad6/7, and then R-Smad activation
is inhibited (Derynck and Zhang, 2003). The activated ERK
can also phosphorylate 4E-BP1, S6K, and MNK. MNK can
directly phosphorylate eIF-4E (Sang et al., 2003), thereby
eventually translating mRNA into HIF-1α protein. Therefore,
ERK is involved in HIF-1 protein synthesis, and it regulates
its transcriptional activity (Masoud and Li, 2015). FOXOs
can be regulated by their upstream proteins through several
posttranslational modifications, such as the phosphorylation of
ERK, JNK, p38, NLK, and AMPK. Among these modifications,
the effect of ERK on FOXO is inhibition (Eijkelenboom
and Burgering, 2013). JNK and p38 can activate p53 by
phosphorylation and then regulate p53 signaling pathway,
thereby indirectly affecting cell cycle and cell apoptosis (Harper
and LoGrasso, 2001). MAPK signaling pathway can directly
affect cell cycle and cell apoptosis by activating multiple
transcription factors, and then cell proliferation, differentiation,
apoptosis, inflammation, and other cellular processes are
regulated (Morrison, 2012).
The rhein action on MAPK signaling pathway was reported
in many articles, but the findings were controversial. Although
the majority of researchers believe that rhein inhibits the
phosphorylation of ERK1/2, p38, and JNK, a few studies
determined that rhein increases the activity of these proteins.
Figure 3 shows that rhein is a multitarget molecule, and the
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FIGURE 3 | The regulation of rhein on the crosstalk of MAPK signaling pathway. The MAPK signaling pathway is activated by the membrane receptors of
several pathways, and then its downstream pathways are regulated. Rhein acts on multiple sites of these pathways to exert the extensive and effective
pharmacological activity. The protein marked with star is the target of rhein. Red and green star represent negative and positive regulation, respectively.
result of its effect is not the change of a single pathway but
a regulatory process of dynamic balance. Rhein with different
concentrations also has a different effect. If the activation of the
classic GRB2/SOS-Ras-ERK1/2 pathway is blocked by rhein in
a certain concentration, then the other pathways may become
the compensatory pathway because of the extensive interaction
among pathways. Therefore, the activation of JNK and p38
induced by TGF-β, Wnt, or the other signals, is enhanced.
Similarly, the uncertainty of the effect of rhein on ERK1/2
may also be the comprehensive results of rhein with a certain
concentration. This observation must be further investigated
through experiments. The downstream of this pathway can be
regulated directly by rhein or indirectly by upstream MAPKs.
Because of the uncertainty of regulation on MAPKs, rhein action
on the downstream biological process is also indeterminate.
Therefore, rhein is endowed with a variety of pharmacological
activities due to the diversity of regulation.
Crosstalk of PI3K-AKT Signaling Pathway
PI3K-AKT signaling pathway is another signal transduction
pathway with a wide interaction with other signaling pathways.
Figure 4 shows that this pathway can be activated by multiple
membrane receptors. In addition to the MAPK signaling
pathway, the activated KDR can regulate PI3K-AKT signaling
pathway by activating PI3K. The activated PI3K leads to the
increase of PIP3, thereby activating some important molecules,
such as AKT and Rac (Cross et al., 2003).
As the hub molecule in this pathway, AKT is the bridge of
the extracellular signal and the nuclear gene expression. The
activation of AKT affects some of its downstream pathways. In
addition to its parallel MAPK signaling pathway, Wnt, NF-κB,
and FOXO signaling pathways are regulated by the activated
AKT. The activated AKT can inhibit the important molecule
GSK3 ofWnt signal pathway, and it then promotesWnt signaling
pathway (Cohen and Frame, 2001). GSK3 phosphorylates
β-catenin when the Wnt ligand is absent, thereby resulting in
β-catenin degradation, which can lead to the inhibition of Wnt
signaling pathway (Jope and Johnson, 2004). The activated AKT
can regulate IKK activity through direct or indirect ways (Kane
et al., 1999). IKK is an upstream regulator of IκB, and it can
lead to IκB degradation via phosphorylation. This series of events
results in the activation of NF-κB signaling pathway. The effect
of the activated AKT on HIF-1 signaling pathway is similar
to the regulation of ERK on HIF-1α. AKT indirectly activates
mTOR, which plays similar functions of ERK, thereby eventually
activating HIF-1 signaling pathway (Richardson et al., 2004). In
addition, the activated AKT can phosphorylate MDM2, thereby
resulting in p53 degradation and then in p53 signaling pathway
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FIGURE 4 | The regulation of rhein on the crosstalk of PI3K-AKT signaling pathway. In this pathway, AKT is the bridge of the extracellular signal and the
nuclear gene expression, affecting some of its downstream pathways. The regulation of rhein on these pathways is probably because of the indirect influence of rhein
through hub AKT protein mediation or the direct action to the AKT downstream protein. The protein marked with star is the target of rhein. Red and green star
represent negative and positive regulation, respectively.
inhibition (Vivanco and Sawyers, 2002). FOXO is an important
target of AKT. AKT promotes G1/S phase transition by blocking
the transcription of FOXO, which mediates cell cycle inhibitor,
such as p27Kip1 and RBL2 (Burgering and Medema, 2003).
AKT also promotes cell survival by blocking the FOXO-mediated
proapoptotic protein, such as Fas-L and Bim (Engelman et al.,
2006). In fact, AKT not only indirectly affects cell cycle and
apoptosis by mediating FOXO transcription factors, but also
directly inhibits p27Kip1 and p21Cip1 to promote cell cycle
progression in cell cycle (Engelman et al., 2006), and suppresses
Bad and Caspase-9 to promote cell survival in apoptosis (Datta
et al., 1997; Cardone et al., 1998).
The effect of rhein on AKT is similar to the effect on the
interaction of the three MAPK cascades. The activation or
inhibition of AKT may also be the result of the comprehensive
effects of rhein on the PI3K-AKT signaling pathway and
on its interaction pathways. In addition, rhein affects several
downstream targets of AKT and some of its downstream
pathways. This phenomenon occurs probably because of the
indirect influence of rhein through hub AKT protein mediation
or the direct action to the AKT downstream protein. Likewise,
the uncertainty and variousness of rhein regulation result in the
diversity of pharmacological activities.
Crosstalk of Cell Cycle
As an important cellular process, cell cycle is affected by
several upstream pathways. Cell cycle mainly manifests
the performances for the regulation on cyclins and CDKs.
By comparing the regulations of p42/p44MAPK and
p38/HOGMAPK cascades on the activity and expression of cyclin
D1 in CCL39 cells, researchers determined that p42/p44MAPK
cascade can increase the activity and expression of cyclin D1,
whereas the result of p38/HOGMAPK cascade is the opposite
(Lavoie et al., 1996). The continuous activation of MAPK leads
to cell proliferation when passing the restriction point of cell
cycle (Fernandes et al., 1999; Hulleman and Boonstra, 2001).
PI3K-AKT signaling pathway affects the transcription of cell
cycle inhibitors. The activated AKT can directly or indirectly
inhibit p21Cip1 and p27Kip1, thereby promoting cell cycle
progression (Engelman et al., 2006). The transcription factor
TCF/LEF affects cell cycle progression through the expression of
cyclin D and c-myc when the classical Wnt signal is transmitted
to the nucleus (Kim et al., 2013). The complexes of Smad2/3 and
Smad4 in TGF-β signal pathway are transferred to the nucleus,
and they increase the expression of c-myc, p15, and p21, thereby
blocking cell progression (Siegel and Massagué, 2003). AMPK
signaling pathway is involved in the inhibition of neural stem cell
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growth and cell cycle arrest by downregulating p-Rb and cyclin
D (Zang et al., 2009). p53 signaling pathway can induce G1 phase
arrest through p21 expression. DNA damage can activate ATM
activity. Subsequently, ATM activates Chk2 via phosphorylation.
Chk2 can activate the p53; it can also inactivate the Cdc25A via
phosphorylation to regulate the cyclin–CDK complex (Taylor
and Stark, 2001). In addition, FOXO, HIF-1, and PPAR signaling
pathways can directly or indirectly interact with cell cycle to
affect cell progression by regulating the expression of cyclins and
their inhibitors (Harris, 2002; Fujii et al., 2004; Shao et al., 2016).
Therefore, the effect of rhein on cell cycle is the comprehensive
and essential regulation of multiple upstream pathways in
addition to the self-regulation on cyclins, CDKs, and CKIs.
In fact, rhein is always represent as the induction of cell cycle
arrest while the regulation on the upstream pathways is not
all consistent with it. For instance, rhein can upregulate Wnt
signaling pathway, while Wnt signal can promote the expression
of cyclin D and c-myc advancing cell process (Kim et al., 2013).
Benefiting from the robustness of biological networks, rhein can
still effectively exert its antitumor activity.
Crosstalk of Apoptosis
Apoptosis is another important cellular process. Cell cycle arrest
is often accompanied by apoptosis, and apoptosis can cause cell
growth arrest (Rubin et al., 1993). The level of apoptosis regulator
Bcl-2 plays an important role in apoptosis. The expression and
activity of Bcl-2 can be directly or indirectly affected by multiple
pathways. The activation of ERK1/2 leads to the upregulation
of Bcl-2 transcriptional activity. The phosphorylated Bcl-2
inhibits proapoptotic proteins and blocks the positive feedback
to promote ERK1/2 activation (Liu et al., 2013). JNK and
p38 are different from ERK1/2. They inhibit the expression
of the prosurvival gene Bcl-2 and increase the expression of
proapoptotic genes, such as p53, Fas, Fas-L, and Bim, to induce
apoptosis (Chen and Chang, 2010; Hui et al., 2014; Yang and
Yao, 2015). AKT can inhibit the proapoptotic gene Bad via
phosphorylation to activate the prosurvival gene Bcl-2 indirectly,
and phosphorylate CREB to increase the expression of Bcl-2
(Wang et al., 2016). Under hypoxia induction, HIF-1 dependent
signal cascade is activated to increase the expression of Bcl-2
protein (Yang et al., 2009). Under the transcriptional control
of Smad3–Smad4 signal, the upregulation of Bcl-2-interacting
mediator Bim is the key of the apoptosis of Hep3B cells
induced by TGF-β (Yu et al., 2008). UPR activates CHOP when
the accumulation of unfolded proteins leads to endoplasmic
reticulum stress, thereby inhibiting Bcl-2 (Malhi and Kaufman,
2011; Schönthal, 2012). In addition to the regulation to Bcl-
2, NF-κB can express the prosurvival gene Bcl-XL to promote
cell survival (Barroso-González et al., 2016). FOXO and p53
signaling pathways regulate the proapoptotic gene to promote
cell apoptosis. For example, the FOXO gene can express Fas-L
and Bim (Gilley et al., 2003), whereas the p53 gene can express
Fas and Bax (Guo et al., 2014; Liao et al., 2016). Similar to
the cell cycle, rhein directly affects multiple targets in apoptosis
process and exerts the comprehensive regulation of multiple
upstream pathways on the expression of apoptosis proteins.
These mediation mechanisms provide a robust support for rhein
to exert antitumor activity.
Crosstalk of Other Pathways
In addition to the wide range of interactive pathways, such
as MAPK and PI3K-AKT signaling pathways, some certain
relationship exists among other signaling pathways. The Smad3/4
complex in TGF-β signaling pathway can bind to the β-catenin
of Wnt signaling pathway with high affinity to block the
transcriptional activity of TCF/LEF (Li et al., 2004). The crosstalk
between AMPK and FOXO signaling pathways also exists. In
differentiated muscle cells, AMPK can increase the content and
transcription of FOXO mRNA (Nystrom and Lang, 2008). In
addition, NF-κB signaling pathway promotes HIF-1 signaling
pathway, which can regulate VEGF signaling pathway. In
malignant lymphoma cells, the abnormal activation of HIF-
1 is partly attributed to NF-κB activation (Qiao et al., 2010),
whereas HIF-1 can express VEGF to promote angiogenesis in
hypoxia (Chen et al., 2015). This finding further indicates that
the regulation of rhein on certain pathways can affect the results
of the other pathway processes.
RHEIN REGULATION ON THE WHOLE
BIOLOGICAL NETWORK
The rhein-mediated biological network is vast and complex. As
shown in Figure 2, the pathways which are related to the targets
of rhein, are initiated by the membrane receptor. Then, MAPK
and PI3K-AKT parallel signaling pathways are activated, and
several downstream pathways are affected, thereby eventually
regulating the cell cycle and apoptosis. The regulation of rhein on
membrane receptors is always negative, which maybe attributes
to its competitive antagonism on natural ligands. According to
the extensive interaction among upstream biological networks,
it is always uncertain about the regulation of rhein on hub
proteins, such as MAPKs and AKT. The regulation of rhein on
downstream pathways of the hub proteins is also indeterminate
due to the diversity of regulation. These downstream biological
processes can be regulated indirectly by the hub proteins or
directly by rhein. However, the regulation of rhein is always
relatively stable on the end of signal transduction, cell cycle and
apoptosis because of the robustness and adaptability of biological
networks.
Rhein is a multi-target molecule regulating multi-pathways
at the molecular level. The therapeutic effect of rhein is the
synergistic and comprehensive result of the involvement of
multiple pathways. If one signal pathway is blocked in two
parallel pathways, the other one may become a compensatory
pathway. This phenomenon is a possible reason for the poor
efficacy of single target drugs. For example, rhein can block the
multiple sites of MAPK signaling pathway, thereby resulting in
anti-inflammatory and antitumor effects (Martin et al., 2003).
This scenario may only be a part of the explanation for the
efficacy of rhein. Rhein blocks the two parallel pathways of
MAPK and PI3K-AKT signaling pathways (Cong et al., 2012a),
and hence it has effective anti-inflammatory and antitumor
effects. In brief, the perturbation of multiple targets gives
rhein a various and effective pharmacological activity, and
the perturbation of a single target cannot determine the
pharmacological properties of rhein.
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It is notable that the impact of drug concentration on
the therapeutic effect is also essential. For example, the low
concentration of rhein inhibits cell proliferation by blocking
MAPKs, whereas the result of rhein with high concentration is on
the contrary (Lin et al., 2003a; Aviello et al., 2010). In addition, the
low concentration of rhein induces the mitochondrial membrane
permeability to release ROS-inducing apoptosis, whereas rhein
with high concentration exerts its reducibility to inhibit ROS (Lai
et al., 2009; Zhao et al., 2011).
CONCLUSION
Rhein has extensive pharmacological activities, and its
mechanisms are complex and interrelated. The mechanisms of
rhein are involved in the multipathways which contain close
interactions. The therapeutic effect of rhein is the synergistic and
comprehensive result of the involvement of multiple pathways
rather than the blocking or activation of a single signaling
pathway. The effects of rhein with different concentrations
on the pathway may vary. In this review, the pharmacological
mechanisms of rhein are summarized from a systematic and
holistic perspective, thereby providing an important reference
for precise treatment and individualized drug administering.
AUTHOR CONTRIBUTIONS
Conceived and designed the experiments: ZX andDC. Performed
the experiments: HS, GL, and DC. Wrote the paper: HS and ZX.
REFERENCES
Aviello, G., Rowland, I., Gill, C. I., Acquaviva, A. M., Capasso, F., McCann, M.,
et al. (2010). Anti-proliferative effect of rhein, an anthraquinone isolated from
Cassia species, on Caco-2 human adenocarcinoma cells. J. Cell. Mol. Med. 14,
2006–2014. doi: 10.1111/j.1582-4934.2009.00815.x
Barroso-González, J., Auclair, S., Luan, S., Thomas, L., Atkins, K. M., Aslan, J. E.,
et al. (2016). PACS-2 mediates the ATM and NF-kappaB-dependent induction
of anti-apoptotic Bcl-xL in response to DNA damage. Cell Death Differ. doi:
10.1038/cdd.2016.23. [Epub ahead of print].
Bikkavilli, R. K., Feigin, M. E., andMalbon, C. C. (2008). G alpha omediatesWNT-
JNK signaling through dishevelled 1 and 3, RhoA family members, and MEKK
1 and 4 in mammalian cells. J. Cell. Sci. 121, 234–245. doi: 10.1242/jcs.021964
Bironaite, D., and Ollinger, K. (1997). The hepatotoxicity of rhein involves
impairment of mitochondrial functions. Chem. Biol. Interact. 103, 35–50. doi:
10.1016/S0009-2797(96)03747-7
Bounda, G. A., Zhou, W., Wang, D. D., and Yu, F. (2015). Rhein elicits in
vitro cytotoxicity in primary human liver HL-7702 cells by inducing apoptosis
through mitochondria-mediated pathway. Evid. Based Complement. Altern.
Med. 2015:329831. doi: 10.1155/2015/329831
Burgering, B. M. T., andMedema, R. H. (2003). Decisions on life and death: FOXO
Forkhead transcription factors are in command when PKB/Akt is off duty. J.
Leukocyte. Biol. 73, 689–701. doi: 10.1189/jlb.1202629
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge,
E., et al. (1998). Regulation of cell death protease caspase-9 by phosphorylation.
Science 282, 1318–1321. doi: 10.1126/science.282.5392.1318
Chang, C. Y., Chan, H. L., Lin, H. Y., Way, T. D., Kao, M. C., Song, M. Z.,
et al. (2012). Rhein induces apoptosis in human breast cancer cells. Evid. Based
Complement. Altern. Med. 2012:952504. doi: 10.1155/2012/952504
Chen, K. C., and Chang, L. S. (2010). Notexin upregulates Fas and
FasL protein expression of human neuroblastoma SK-N-SH cells through
p38 MAPK/ATF-2 and JNK/c-Jun pathways. Toxicon 55, 754–761. doi:
10.1016/j.toxicon.2009.11.008
Chen, M. C., Hsu, W. L., Hwang, P. A., and Chou, T. C. (2015). Low molecular
weight fucoidan inhibits tumor angiogenesis through downregulation of
HIF-1/VEGF signaling under hypoxia. Mar. Drugs 13, 4436–4451. doi:
10.3390/md13074436
Cheng, Y. H., Lai, S. W., Chen, P. Y., Chang, J. H., and Chang, N. W. (2015).
PPAR alpha activation attenuates amyloid-beta-dependent neurodegeneration
by modulating endo G and AIF translocation. Neurotox. Res. 27, 55–68. doi:
10.1007/s12640-014-9485-9
Chipuk, J. E., and Green, D. R. (2009). PUMA cooperates with direct activator
proteins to promote mitochondrial outer membrane permeabilization and
apoptosis. Cell Cycle 8, 2692–2696. doi: 10.4161/cc.8.17.9412
Cohen, P., and Frame, S. (2001). The renaissance of GSK3.Nat. Rev. Mol. Cell Biol.
2, 769–776. doi: 10.1038/35096075
Cong, X. D., Ding, M. J., Dai, D. Z., Wu, Y., Zhang, Y., and Dai, Y. (2012a). ER
stress, P66shc, and P-Akt/Akt mediate adjuvant-induced inflammation, which
is blunted by argirein, a supermolecule and rhein in rats. Inflammation 35,
1031–1040. doi: 10.1007/s10753-011-9407-4
Cong, X. D., Wu, Y., Dai, D. Z., Ding, M. J., Zhang, Y., and Dai, Y.
(2012b). Activation of AQP4, p66Shc and endoplasmic reticulum stress is
involved in inflammation by carrageenan and is suppressed by argirein, a
derivative of rhein. J. Pharm. Pharmacol. 64, 1138–1145. doi: 10.1111/j.2042-
7158.2012.01507.x
Cross, M. J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003).
VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488–494. doi:
10.1016/S0968-0004(03)00193-2
Cullen, S. P., Brunet, M., and Martin, S. J. (2010). Granzymes in cancer and
immunity. Cell Death Differ. 17, 616–623. doi: 10.1038/cdd.2009.206
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., et al. (1997). Akt
phosphorylation of BAD couples survival signals to the cell-intrinsic death
machinery. Cell 91, 231–241. doi: 10.1016/S0092-8674(00)80405-5
Deffaud, J., Kirchmeyer, M., Domagala, F., Ficheux, H., Netter, P., Bianchi, A., et al.
(2008). Modulatory effect of rhein on IL-1 alpha-induced responses in human
chondrocytes: a comparative study between antibody microarrays and specific
ELISAs. Biorheology 45, 439–455. doi: 10.3233/Bir-2008-0484
Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent
pathways in TGF-beta family signalling. Nature 425, 577–584. doi:
10.1038/nature02006
Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated receptors:
nuclear control of metabolism. Endocr. Rev. 20, 649–688. doi: 10.1210/
er.20.5.649
Du, Q., Bian, X. L., Xu, X. L., Zhu, B., Yu, B., and Zhai, Q. (2013).
Role of mitochondrial permeability transition in human hepatocellular
carcinoma Hep-G2 cell death induced by rhein. Fitoterapia 91, 68–73. doi:
10.1016/j.fitote.2013.08.008
Eijkelenboom, A., and Burgering, B. M. (2013). FOXOs: signalling integrators
for homeostasis maintenance. Nat. Rev. Mol. Cell Biol. 14, 83–97. doi:
10.1038/nrm3507
Engelman, J. A., Luo, J., and Cantley, L. C. (2006). The evolution of
phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat.
Rev. Genet. 7, 606–619. doi: 10.1038/nrg1879
Ersahin, T., Tuncbag, N., and Cetin-Atalay, R. (2015). The PI3K/AKT/mTOR
interactive pathway.Mol. Biosyst. 11, 1946–1954. doi: 10.1039/C5MB00101C
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., and Wahli, W. (2006). From
molecular action to physiological outputs: peroxisome proliferator-activated
receptors are nuclear receptors at the crossroads of key cellular functions. Prog.
Lipid Res. 45, 120–159. doi: 10.1016/j.plipres.2005.12.002
Fernand, V. E., Losso, J. N., Truax, R. E., Villar, E. E., Bwambok, D. K.,
Fakayode, S. O., et al. (2011). Rhein inhibits angiogenesis and the viability
of hormone-dependent and -independent cancer cells under normoxic or
hypoxic conditions in vitro. Chem. Biol. Interact. 192, 220–232. doi: 10.1016/
j.cbi.2011.03.013
Fernandes, D., Guida, E., Koutsoubos, V., Harris, T., Vadiveloo, P., Wilson, J. W.,
et al. (1999). Glucocorticoids inhibit proliferation, cyclin D1 expression, and
Frontiers in Pharmacology | www.frontiersin.org 12 August 2016 | Volume 7 | Article 247
Sun et al. Rhein: A Comprehensive and System Review
retinoblastoma protein phosphorylation, but not activity of the extracellular-
regulated kinases in human cultured airway smooth muscle. Am. J. Respir. Cell
Mol. Biol. 21, 77–88. doi: 10.1165/ajrcmb.21.1.3396
Fujii, D., Yoshida, K., Tanabe, K., Hihara, J., and Toge, T. (2004). The ligands
of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth
of human esophageal carcinoma cells through induction of apoptosis and cell
cycle arrest. Anticancer Res. 24, 1409–1416.
Gallenne, T., Gautier, F., Oliver, L., Hervouet, E., Noël, B., Hickman, J. A.,
et al. (2009). Bax activation by the BH3-only protein Puma promotes cell
dependence on antiapoptotic Bcl-2 family members. J. Cell. Biol. 185, 279–290.
doi: 10.1083/jcb.200809153
Gao, Q., Qin, W. S., Jia, Z. H., Zheng, J. M., Zeng, C. H., Li, L. S., et al. (2010).
Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with
diabetic nephropathy. Planta Med. 76, 27–33. doi: 10.1055/s-0029-1185948
Gao, Y., Chen, X., Fang, L., Liu, F., Cai, R. L., Peng, C., et al. (2014). Rhein
exerts pro- and anti-inflammatory actions by targeting IKK beta inhibition
in LPS-activated macrophages. Free Radic. Biol. Med. 72, 104–112. doi:
10.1016/j.freeradbiomed.2014.04.001
Ge, J. H., Liu, X. H., Xu, H., Xu, D. Y., and Bai, F. P. (2015). Identification of
different varieties of Rhei Radix et Rhizoma based on chemical analysis. Chin.
J. Chin. Mat. Med. 40, 2309–2313.
Ge, X., Luo, X. F., Chen, Y. G., Li, M. Q., Jiang, S. X., andWang, X. S. (2011). Rhein
induces apoptosis of HCT-116 human colon cancer cells via activation of the
intrinsic apoptotic pathway. Afr. J. Biotechnol. 10, 13244–13251.
Gilley, J., Coffer, P. J., and Ham, J. (2003). FOXO transcription factors directly
activate bim gene expression and promote apoptosis in sympathetic neurons.
J. Cell. Biol. 162, 613–622. doi: 10.1083/jcb.200303026
Glauser, D. A., and Schlegel, W. (2007). The emerging role of FOXO transcription
factors in pancreatic beta cells. J. Endocrinol. 193, 195–207. doi: 10.1677/JOE-
06-0191
Gong, H. L., Tang, W. F., Wang, J., Chen, G. Y., and Huang, X. (2012).
Effect of formula compatibility on the pharmacokinetics of components from
Dachengqi Decoction [See Text] in rats. Chin. J. Integr. Med. 18, 708–713. doi:
10.1007/s11655-012-1205-9
Guo, M. Z., Li, X. S., Xu, H. R., Mei, Z. C., Shen, W., and Ye, X. F. (2002). Rhein
inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol.
Sin. 23, 739–744.
Guo, X. H., Liu, Z. H., Dai, C. S., Li, H., Liu, D., and Li, L. S. (2001). Rhein inhibits
renal tubular epithelial cell hypertrophy and extracellular matrix accumulation
induced by transforming growth factor beta(1). Acta Pharmacol. Sin. 22,
934–938.
Guo, X. X., Li, Y., Sun, C., Jiang, D., Lin, Y. J., Jin, F. X., et al. (2014). p53-dependent
Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in
HeLa cells. Protein Cell 5, 224–234. doi: 10.1007/s13238-014-0027-2
Hardie, D. G. (2004). The AMP-activated protein kinase pathway–new players
upstream and downstream. J. Cell. Sci. 117, 5479–5487. doi: 10.1242/jcs.
01540
Harper, S. J., and LoGrasso, P. (2001). Signalling for survival and death in neurones:
the role of stress-activated kinases, JNK and p38. Cell. Signal. 13, 299–310. doi:
10.1016/S0898-6568(01)00148-6
Harris, A. L. (2002). Hypoxia–a key regulatory factor in tumour growth. Nat. Rev.
Cancer 2, 38–47. doi: 10.1038/nrc704
Harris, S. L., and Levine, A. J. (2005). The p53 pathway: positive and negative
feedback loops. Oncogene 24, 2899–2908. doi: 10.1038/sj.onc.1208615
Hatsell, S., Rowlands, T., Hiremath, M., and Cowin, P. (2003). Beta-catenin and
Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia
8, 145–158. doi: 10.1023/A:1025944723047
He, D. Y., Lee, L., Yang, J. W., and Wang, X. Y. (2011). Preventive effects and
mechanisms of rhein on renal interstitial fibrosis in obstructive nephropathy.
Biol. Pharm. Bull. 34, 1219–1226. doi: 10.1248/bpb.34.1219
He, Z. H., Zhou, R., He,M. F., Lau, C. B. S., Yue, G. G. L., Ge,W., et al. (2011). Anti-
angiogenic effect and mechanism of rhein from Rhizoma Rhei. Phytomedicine
18, 470–478. doi: 10.1016/j.phymed.2010.10.006
Heo, S. K., Yun, H. J., Noh, E. K., and Park, S. D. (2010). Emodin and rhein inhibit
LIGHT-induced monocytes migration by blocking of ROS production. Vasc.
Pharmacol. 53, 28–37. doi: 10.1016/j.vph.2010.03.002
Heo, S. K., Yun, H. J., Park, W. H., and Park, S. D. (2009). Rhein
inhibits TNF-alpha-induced human aortic smooth muscle cell proliferation
via mitochondrial-dependent apoptosis. J. Vasc. Res. 46, 375–386. doi:
10.1159/000189798
Hevner, R. F. (2015). Brain overgrowth in disorders of RTK-PI3K-AKT signaling:
a mosaic of malformations. Semin. Perinatol. 39, 36–43. doi: 10.1053/
j.semperi.2014.10.006
Hsia, T. C., Yang, J. S., Chen, G. W., Chiu, T. H., Lu, H. F., Yang, M. D., et al.
(2009). The roles of endoplasmic reticulum stress and Ca2+ on Rhein-induced
apoptosis in A-549 human lung cancer cells. Anticancer Res. 29, 309–318.
Hu, C., Cong, X. D., Dai, D. Z., Zhang, Y., Zhang, G. L., and Dai, Y. (2011).
Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase,
Cx43, and PERK in renal tissue. Naunyn-Schmiedebergs Arch. Pharmacol. 383,
309–319. doi: 10.1007/s00210-010-0593-7
Hu, G., Liu, J., Zhen, Y. Z., Wei, J., Qiao, Y., Lin, Y. J., et al. (2013). Rhein inhibits
the expression of vascular cell adhesion molecule 1 in human umbilical vein
endothelial cells with or without lipopolysaccharide stimulation. Am. J. Chin.
Med. 41, 473–485. doi: 10.1142/S0192415X13500341
Hui, K., Yang, Y., Shi, K., Luo, H., Duan, J., An, J., et al. (2014). The p38
MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced
colorectal cancer cell apoptosis in vitro and in vivo. Cancer Lett. 354, 189–199.
doi: 10.1016/j.canlet.2014.08.009
Hulleman, E., and Boonstra, J. (2001). Regulation of G1 phase progression by
growth factors and the extracellular matrix. Cell. Mol. Life Sci. 58, 80–93. doi:
10.1007/PL00000780
Inokuchi-Shimizu, S., Park, E. J., Roh, Y. S., Yang, L., Zhang, B., Song, J.,
et al. (2014). TAK1-mediated autophagy and fatty acid oxidation prevent
hepatosteatosis and tumorigenesis. J. Clin. Invest. 124, 3566–3578. doi:
10.1172/JCI74068
Ip, S. W., Weng, Y. S., Lin, S. Y., Mei-Dueyang, Tang, N. Y., Su, C. C., et al. (2007).
The role of Ca+2 on rhein-induced apoptosis in human cervical cancer Ca Ski
cells. Anticancer Res. 27, 379–389.
Jeong, S. Y., and Seol, D. W. (2008). The role of mitochondria in apoptosis. BMB
Rep. 41, 11–22. doi: 10.5483/BMBRep.2008.41.1.011
Jope, R. S., and Johnson, G. V. W. (2004). The glamour and gloom
of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95–102. doi:
10.1016/j.tibs.2003.12.004
Kane, L. P., Shapiro, V. S., Stokoe, D., and Weiss, A. (1999). Induction of NF-
kappaB by the Akt/PKB kinase. Curr. Biol. 9, 601–604. doi: 10.1016/S0960-
9822(99)80265-6
Ke, H., Masoumi, K. C., Ahlqvist, K., Seckl, M. J., Rydell-Törmänen, K., and
Massoumi, R. (2016). Nemo-like kinase regulates the expression of vascular
endothelial growth factor (VEGF) in alveolar epithelial cells. Sci. Rep. 6:23987.
doi: 10.1038/srep23987
Kim, K., Fisher, M. J., Xu, S. Q., and el-Deiry,W. S. (2000). Molecular determinants
of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6,
335–346.
Kim, Y.M., Kim, I. H., and Nam, T. J. (2013). Capsosiphon fulvescens glycoprotein
inhibits AGS gastric cancer cell proliferation by downregulating Wnt-1
signaling. Int. J. Oncol. 43, 1395–1401. doi: 10.3892/ijo.2013.2079
Kuo, P. L., Hsu, Y. L., Ng, L. T., and Lin, C. C. (2004). Rhein inhibits the
growth and induces the apoptosis of Hep G2 cells. Planta Med. 70, 12–16. doi:
10.1055/s-2004-815448
Lai, W. W., Yang, J. S., Lai, K. C., Kuo, C. L., Hsu, C. K., Wang, C. K., et al. (2009).
Rhein induced apoptosis through the endoplasmic reticulum stress, caspase-
and mitochondria-dependent pathways in SCC-4 human tongue squamous
cancer cells. In Vivo 23, 309–316.
Lamalice, L., Houle, F., and Huot, J. (2006). Phosphorylation of Tyr1214 within
VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to
SAPK2/p38 activation and endothelial cell migration in response to VEGF. J.
Biol. Chem. 281, 34009–34020. doi: 10.1074/jbc.M603928200
Lavoie, J. N., L’Allemain, G., Brunet, A., Müller, R., and Pouysségur, J. (1996).
Cyclin D1 expression is regulated positively by the p42/p44MAPK and
negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271, 20608–20616.
doi: 10.1074/jbc.271.34.20608
Lavrik, I., Golks, A., and Krammer, P. H. (2005). Death receptor signaling. J. Cell
Sci. 118, 265–267. doi: 10.1242/jcs.01610
Lee, J. W., Bae, S. H., Jeong, J. W., Kim, S. H., and Kim, K. W. (2004). Hypoxia-
inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp.
Mol. Med. 36, 1–12. doi: 10.1038/emm.2004.1
Frontiers in Pharmacology | www.frontiersin.org 13 August 2016 | Volume 7 | Article 247
Sun et al. Rhein: A Comprehensive and System Review
Legendre, F., Bogdanowicz, P., Martin, G., Domagala, F., Leclercq, S., Pujol,
J. P., et al. (2007). Rhein, a diacerhein-derived metabolite, modulates the
expression of matrix degrading enzymes and the cell proliferation of articular
chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin. Exp.
Rheumatol. 25, 546–555.
Legendre, F., Heuze, A., Boukerrouche, K., Leclercq, S., Boumediene, K., Galera,
P., et al. (2009). Rhein, the metabolite of diacerhein, reduces the proliferation
of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis.
Scand. J. Rheumatol. 38, 104–111. doi: 10.1080/03009740802421996
Levkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K.,
et al. (1998). Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in
endothelial cells through activation of Cdk2: role of a caspase cascade.Mol. Cell
1, 553–563. doi: 10.1016/S1097-2765(00)80055-6
Li, H., Guo, H., Wu, L., Zhang, Y., Chen, J., Liu, X., et al. (2013). Comparative
pharmacokinetics study of three anthraquinones in rat plasma after oral
administration of Radix et Rhei Rhizoma extract and Dahuang Fuzi Tang
by high performance liquid chromatography-mass spectrometry. J. Pharm.
Biomed. Anal. 76, 215–218. doi: 10.1016/j.jpba.2012.12.004
Li, Q., Dashwood, W. M., Zhong, X., Al-Fageeh, M., and Dashwood, R. H. (2004).
Cloning of the rat beta-catenin gene (Ctnnb1) promoter and its functional
analysis compared with the Catnb and CTNNB1 promoters. Genomics 83,
231–242. doi: 10.1016/j.ygeno.2003.08.004
Li, Y. W., Xu, Y. Q., Lei, B., Wang, W. X., Ge, X., and Li, J. R. (2012).
Rhein induces apoptosis of human gastric cancer SGC-7901 cells via an
intrinsic mitochondrial pathway. Brazilian J. Med. Biol. Res. 45, 1052–1059. doi:
10.1590/S0100-879X2012007500125
Li, Y. X., Gong, X. H., Li, Y., Zhang, R. Q., Yuan, A., Zhao, M. J., et al.
(2015). The influence of aconitum carmichaelii debx. on the pharmacokinetic
characteristics of main components in Rheum palmatum L. Phytother. Res. 29,
1259–1264. doi: 10.1002/ptr.5369
Liao, J. M., Cao, B., Deng, J., Zhou, X., Strong, M., Zeng, S., et al. (2016). TFIIS.h, a
new target of p53, regulates transcription efficiency of pro-apoptotic bax gene.
Sci. Rep. 6:23542. doi: 10.1038/srep23542
Lim, S., and Kaldis, P. (2013). Cdks, cyclins and CKIs: roles beyond cell cycle
regulation. Development 140, 3079–3093. doi: 10.1242/dev.091744
Lin, M. L., Chen, S. S., Lu, Y. C., Liang, R. Y., Ho, Y. T., Yang, C. Y., et al. (2007).
Rhein induces apoptosis through induction of endoplasmic reticulum stress
and Ca2+-dependent mitochondrial death pathway in human nasopharyngeal
carcinoma cells. Anticancer Res. 27, 3313–3322.
Lin, M. L., Chung, J. G., Lu, Y. C., Yang, C. Y., and Chen, S. S. (2009).
Rhein inhibits invasion and migration of human nasopharyngeal carcinoma
cells in vitro by down-regulation of matrix metalloproteinases-9 and
vascular endothelial growth factor. Oral Oncol. 45, 531–537. doi: 10.1016/
j.oraloncology.2008.07.012
Lin, S. G., Fujii, M., and Hou, D. X. (2003a). Rhein induces apoptosis in HL-60 cells
via reactive oxygen species-independent mitochondrial death pathway. Arch.
Biochem. Biophys. 418, 99–107. doi: 10.1016/j.abb.2003.08.004
Lin, S. G., Li, J. J., Fujii, M., and Hou, D. X. (2003b). Rhein inhibits TPA-
induced activator protein-1 activation and cell transformation by blocking the
JNK-dependent pathway. Int. J. Oncol. 22, 829–833. doi: 10.3892/ijo.22.4.829
Liu, Q., Zhang, X. L., Tao, R. Y., Niu, Y. J., Chen, X. G., Tian, J. Y., et al. (2011).
Rhein, an inhibitor of adipocyte differentiation and adipogenesis. J. Asian Nat.
Prod. Res. 13, 714–723. doi: 10.1080/10286020.2011.586341
Liu, Y., Zhang, Z., Song, T., Liang, F., Xie, M., and Sheng, H. (2013). Resistance
to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2
through ERK1/2. Br. J. Pharmacol. 169, 1612–1623. doi: 10.1111/bph.12243
Liu, Z. H., Li, Y. J., Chen, Z. H., Liu, D., and Li, L. S. (2001). Glucose transporter
in human glomerular mesangial cells modulated by transforming growth factor
beta and rhein. Acta Pharmacol. Sin. 22, 169–175.
Malhi, H., and Kaufman, R. J. (2011). Endoplasmic reticulum stress in liver disease.
J. Hepatol. 54, 795–809. doi: 10.1016/j.jhep.2010.11.005
Malhotra, J. D., and Kaufman, R. J. (2007). The endoplasmic reticulum and
the unfolded protein response. Semin. Cell Dev. Biol. 18, 716–731. doi:
10.1016/j.semcdb.2007.09.003
Martel-Pelletier, J., Mineau, F., Caron, J., and Pelletier, J. P. (2011). Effect of
diacerein/rhein on the Wnt system in human osteoarthritic subchondral bone.
Osteoarthr. Cartil. 19, S123–S123. doi: 10.1016/S1063-4584(11)60283-5
Martin, G., Bogdanowicz, P., Domagala, F., Ficheux, H., and Pujol, J. P. (2003).
Rhein inhibits interleukin-1 beta-induced activation ofMEK/ERK pathway and
DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia:
a potential mechanism for its disease-modifying effect in osteoarthritis.
Inflammation 27, 233–246. doi: 10.1023/A:1025040631514
Martin, G., Bogdanowicz, P., Domagala, F., Ficheux, H., and Pujol, J. P. (2004).
Articular chondrocytes cultured in hypoxia: their response to interleukin-1 beta
and rhein, the active metabolite of diacerhein. Biorheology 41, 549–561.
Masoud, G. N., and Li, W. (2015). HIF-1alpha pathway: role, regulation and
intervention for cancer therapy. Acta Pharm. Sin. B. 5, 378–389. doi:
10.1016/j.apsb.2015.05.007
Mendes, A. F., Caramona, M. M., de Carvalho, A. P., and Lopes, M. C. (2002).
Diacerhein and rhein prevent interleukin-1 beta-induced nuclear factor-
kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha.
Pharmacol. Toxicol. 91, 22–28. doi: 10.1034/j.1600-0773.2002.910104.x
Meng, Z. Q., Yan, Y. X., Tang, Z. H., Guo, C. R., Li, N., Huang, W. Z., et al. (2015).
Anti-hyperuricemic and nephroprotective effects of rhein in hyperuricemic
mice. Planta Med. 81, 279–285. doi: 10.1055/s-0034-1396241
Moelling, K., Schad, K., Bosse, M., Zimmermann, S., and Schweneker, M.
(2002). Regulation of raf-akt cross-talk. J. Biol. Chem. 277, 31099–31106. doi:
10.1074/jbc.M111974200
Morgan, T. M., Koreckij, T. D., and Corey, E. (2009). Targeted therapy for
advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr.
Cancer Drug Targets 9, 237–249. doi: 10.2174/156800909787580999
Morrison, D. K. (2012). MAP kinase pathways. Cold Spring Harb. Perspect. Biol.
4:a011254. doi: 10.1101/cshperspect.a011254
Moustakas, A., Pardali, K., Gaal, A., andHeldin, C. H. (2002).Mechanisms of TGF-
beta signaling in regulation of cell growth and differentiation. Immunol. Lett.
82, 85–91. doi: 10.1016/S0165-2478(02)00023-8
Nawa, H., Uchibayashi, M., and Matsuoka, T. (1961). Structure of rhein. J. Org.
Chem. 26, 979–981. doi: 10.1021/jo01062a628
Neely, R. J., Brose, M. S., Gray, C. M., McCorkell, K. A., Leibowitz, J. M., Ma,
C., et al. (2011). The RET/PTC3 oncogene activates classical NF-kappaB by
stabilizing NIK. Oncogene 30, 87–96. doi: 10.1038/onc.2010.396
Nigg, E. A. (1995). Cyclin-dependent protein kinases: key regulators of the
eukaryotic cell cycle. Bioessays 17, 471–480. doi: 10.1002/bies.950170603
Niu, S., Kou, S., Zhou, X., and Ding, L. (2012). Heshouwu decoction,
a Chinese herb for tonifying kidney, ameliorates hypothalamic-pituitary-
testicular axis secretion in aging rats. Neural Regen. Res. 7, 1611–1617. doi:
10.3969/j.issn.1673-5374.2012.21.002
Nusse, R. (2005). Wnt signaling in disease and in development. Cell Res. 15, 28–32.
doi: 10.1038/sj.cr.7290260
Nystrom, G. J., and Lang, C. H. (2008). Sepsis and AMPK activation by AICAR
differentially regulate foxO-1, -3 and -4 mRNA in striated muscle. Int. J. Clin.
Exp. Med. 1, 50–63.
Oeckinghaus, A., Hayden, M. S., and Ghosh, S. (2011). Crosstalk in NF-kappaB
signaling pathways. Nat. Immunol. 12, 695–708. doi: 10.1038/ni.2065
Okamoto, A., Hussain, S. P., Hagiwara, K., Spillare, E. A., Rusin, M. R.,
Demetrick, D. J., et al. (1995). Mutations in the p16INK4/MTS1/CDKN2,
p15INK4B/MTS2, and p18 genes in primary andmetastatic lung cancer.Cancer
Res. 55, 1448–1451.
Panigrahi, G. K., Yadav, A., Srivastava, A., Tripathi, A., Raisuddin, S., and Das,
M. (2015). Mechanism of rhein-induced apoptosis in rat primary hepatocytes:
beneficial effect of cyclosporine A. Chem. Res. Toxicol. 28, 1133–1143. doi:
10.1021/acs.chemrestox.5b00063
Peng, S. N., Zeng, H. H., Fu, A. X., Chen, X. W., and Zhu, Q. X. (2013). Protection
of rhein on IgA nephropathy mediated by inhibition of fibronectin expression
in rats. Indian J. Pharmacol. 45, 174–179. doi: 10.4103/0253-7613.108309
Peng, Y. H., Lin, S. P., Yu, C. P., Tsai, S. Y., Chen, M. Y., Hou, Y. C., et al.
(2014). Serum concentrations of anthraquinones after intake of Folium Sennae
and potential modulation on P-glycoprotein. Planta Med. 80, 1291–1297. doi:
10.1055/s-0034-1383040
Perkins, N. D. (2007). Integrating cell-signalling pathways with NF-kappaB and
IKK function. Nat. Rev. Mol. Cell Biol. 8, 49–62. doi: 10.1038/nrm2083
Qiao, Q., Nozaki, Y., Sakoe, K., Komatsu, N., and Kirito, K. (2010). NF-kappaB
mediates aberrant activation of HIF-1 in malignant lymphoma. Exp. Hematol.
38, 1199–1208. doi: 10.1016/j.exphem.2010.08.007
Frontiers in Pharmacology | www.frontiersin.org 14 August 2016 | Volume 7 | Article 247
Sun et al. Rhein: A Comprehensive and System Review
Reubold, T. F., and Eschenburg, S. (2012). A molecular view on signal
transduction by the apoptosome. Cell. Signal. 24, 1420–1425. doi:
10.1016/j.cellsig.2012.03.007
Richardson, C. J., Schalm, S. S., and Blenis, J. (2004). PI3-kinase and
TOR: PIKTORing cell growth. Semin. Cell Dev. Biol. 15, 147–159. doi:
10.1016/j.semcdb.2003.12.023
Rubin, L. L., Philpott, K. L., and Brooks, S. F. (1993). Apoptosis: the cell cycle and
cell death. Curr. Biol. 3, 391–394. doi: 10.1016/0960-9822(93)90211-6
Sanchez, C., Mathy-Hartert, M., Deberg, M. A., Ficheux, H., Reginster, J. Y. L.,
and Henrotin, Y. E. (2003). Effects of rhein on human articular chondrocytes
in alginate beads. Biochem. Pharmacol. 65, 377–388. doi: 10.1016/S0006-
2952(02)01485-5
Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., and Caro,
J. (2003). MAPK signaling up-regulates the activity of hypoxia-inducible
factors by its effects on p300. J. Biol. Chem. 278, 14013–14019. doi:
10.1074/jbc.M209702200
Schleich, K., and Lavrik, I. N. (2013). Mathematical modeling of apoptosis. Cell
Commun. Signal. 11:44. doi: 10.1186/1478-811X-11-44
Schönthal, A. H. (2012). Endoplasmic reticulum stress: its role in disease
and novel prospects for therapy. Scientifica (Cairo). 2012:857516. doi:
10.6064/2012/857516
Semenza, G. L. (2010). Oxygen homeostasis. Wiley Interdiscip. Rev. Syst. Biol. 2,
336–361. doi: 10.1002/wsbm.69
Shao, H., Mohamed, E. M., Xu, G. G., Waters, M., Jing, K., Ma, Y., et al. (2016).
Carnitine palmitoyltransferase 1A functions to repress FoxO transcription
factors to allow cell cycle progression in ovarian cancer. Oncotarget 7,
3832–3846. doi: 10.18632/oncotarget.6757
Sheng, X. Y., Wang, M., Lu, M., Xi, B. L., Sheng, H. G., and Zang, Y.
Q. (2011). Rhein ameliorates fatty liver disease through negative energy
balance, hepatic lipogenic regulation, and immunomodulation in diet-
induced obese mice. Am. J. Physiol.-Endocrinol. Metab. 300, E886–E893. doi:
10.1152/ajpendo.00332.2010
Sherr, C. J., and Roberts, J. M. (1999). CDK inhibitors: positive and negative
regulators of G1-phase progression. Genes Dev. 13, 1501–1512. doi: 10.1101/
gad.13.12.1501
Shi, L. L., Xu, L. N., Hou, S. G., Lin, S., Yang, H., and Ma, T. H. (2006). Activation
effect of cathartic natural compound rhein to CFTR chloride channel. Chem.
Res. Chin. Univ. 22, 312–314. doi: 10.1016/S1005-9040(06)60105-0
Shi, P., Huang, Z. W., and Chen, G. C. (2008). Rhein induces apoptosis and cell
cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am. J. Chin.
Med. 36, 805–813. doi: 10.1142/S0192415X08006259
Shi, Y. G., and Massagué, J. (2003). Mechanisms of TGF-beta signaling from
cell membrane to the nucleus. Cell 113, 685–700. doi: 10.1016/S0092-
8674(03)00432-X
Shinya, T., Yokota, T., Nakayama, S., Oki, S., Mutoh, J., Takahashi, S., et al. (2015).
Orally administered mucolytic drug l-Carbocisteine inhibits angiogenesis
and tumor growth in mice. J. Pharmacol. Exp. Ther. 354, 269–278. doi:
10.1124/jpet.115.224816
Siegel, P. M., andMassagué, J. (2003). Cytostatic and apoptotic actions of TGF-beta
in homeostasis and cancer. Nat. Rev. Cancer 3, 807–821. doi: 10.1038/nrc1208
Stennicke, H. R., Jürgensmeier, J. M., Shin, H., Deveraux, Q., Wolf, B. B., Yang, X.,
et al. (1998). Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol.
Chem. 273, 27084–27090. doi: 10.1074/jbc.273.42.27084
Stolz, A., and Wolf, D. H. (2010). Endoplasmic reticulum associated protein
degradation: a chaperone assisted journey to hell. Biochim. Biophys. Acta Mol.
Cell Res. 1803, 694–705. doi: 10.1016/j.bbamcr.2010.02.005
Su, J., Yin, L. P., Zhang, X., Li, B. B., Liu, L., and Li, H. (2013). Chronic allograft
nephropathy in rats is improved by the intervention of rhein. Transplant. Proc.
45, 2546–2552. doi: 10.1016/j.transproceed.2013.03.030
Takahashi, H., and Shibuya, M. (2005). The vascular endothelial growth
factor (VEGF)/VEGF receptor system and its role under physiological
and pathological conditions. Clin. Sci. 109, 227–241. doi: 10.1042/CS200
40370
Taylor, W. R., and Stark, G. R. (2001). Regulation of the G2/M transition by p53.
Oncogene 20, 1803–1815. doi: 10.1038/sj.onc.1204252
Towler, M. C., and Hardie, D. G. (2007). AMP-activated protein kinase
in metabolic control and insulin signaling. Circ. Res. 100, 328–341. doi:
10.1161/01.RES.0000256090.42690.05
Tsang, S. W., and Bian, Z. X. (2015). Anti-fibrotic and anti-tumorigenic effects
of rhein, a natural anthraquinone derivative, in mammalian stellate and
carcinoma cells. Phytother. Res. 29, 407–414. doi: 10.1002/ptr.5266
Tsang, S. W., Zhang, H. J., Lin, C. Y., Xiao, H. T., Wong, M., Shang, H.
C., et al. (2013). Rhein, a natural anthraquinone derivative, attenuates the
activation of pancreatic stellate cells and ameliorates pancreatic fibrosis
in mice with experimental chronic pancreatitis. PLoS ONE 8:e82201. doi:
10.1371/journal.pone.0082201
Vaidya, A., and Kale, V. P. (2015). TGF-beta signaling and its role in the regulation
of hematopoietic stem cells. Syst. Synth. Biol. 9, 1–10. doi: 10.1007/s11693-015-
9161-2
van der Horst, A., and Burgering, B. M. (2007). Stressing the role of FoxO
proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 8, 440–450. doi:
10.1038/nrm2190
Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT
pathway in human cancer. Nat. Rev. Cancer 2, 489–501. doi: 10.1038/nrc839
Wang, J., Liu, S., Yin, Y. C., Li, M. J., Wang, B., Yang, L., et al. (2015).
FOXO3-mediated up-regulation of Bim contributes to rhein-induced cancer
cell apoptosis. Apoptosis 20, 399–409. doi: 10.1007/s10495-014-1071-3
Wang, L., Tang, L., Wang, Y., Wang, L., Liu, X., Liu, X., et al. (2016). Exendin-4
protects HUVECs from t-BHP-induced apoptosis via PI3K/Akt-Bcl-2-caspase-
3 signaling. Endocr. Res. 41, 229–235. doi: 10.3109/07435800.2015.1110162
Wang, X., Sun, H., Zhang, A., Jiao, G., Sun, W., and Yuan, Y. (2011).
Pharmacokinetics screening for multi-components absorbed in the rat
plasma after oral administration traditional Chinese medicine formula Yin-
Chen-Hao-Tang by ultra performance liquid chromatography-electrospray
ionization/quadrupole-time-of-flight mass spectrometry combined with
pattern recognitionmethods.Analyst 136, 5068–5076. doi: 10.1039/c1an15752c
Wen, X., Lin, Z. Q., Liu, B., andWei, Y. Q. (2012). Caspase-mediated programmed
cell death pathways as potential therapeutic targets in cancer. Cell Prolif. 45,
217–224. doi: 10.1111/j.1365-2184.2012.00814.x
Yang, C. C., Lin, L. C., Wu, M. S., Chien, C. T., and Lai, M. K. (2009).
Repetitive hypoxic preconditioning attenuates renal ischemia/reperfusion
induced oxidative injury via upregulating HIF-1 alpha-dependent bcl-2
signaling. Transplantation 88, 1251–1260. doi: 10.1097/TP.0b013e3181bb4a07
Yang, J., and Yao, S. (2015). JNK-Bcl-2/Bcl-xL-Bax/Bak pathway mediates the
crosstalk between matrine-induced autophagy and apoptosis via interplay with
beclin 1. Int. J. Mol. Sci. 16, 25744–25758. doi: 10.3390/ijms161025744
Yu, C., Qi, D., Sun, J. F., Li, P., and Fan, H. Y. (2015). Rhein prevents endotoxin-
induced acute kidney injury by inhibiting NF-kappa B activities. Sci. Rep.
5:11822. doi: 10.1038/srep11822
Yu, J., Zhang, L., Chen, A., Xiang, G., Wang, Y., Wu, J., et al. (2008). Identification
of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4
signaling. J. Cell. Physiol. 215, 422–433. doi: 10.1002/jcp.21325
Yun, M. S., Kim, S. E., Jeon, S. H., Lee, J. S., and Choi, K. Y. (2005). Both ERK
and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation.
J. Cell. Sci. 118, 313–322. doi: 10.1242/jcs.01601
Zang, Y., Yu, L. F., Nan, F. J., Feng, L. Y., and Li, J. (2009). AMP-activated
protein kinase is involved in neural stem cell growth suppression and cell
cycle arrest by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and
glucose deprivation by down-regulating phospho-retinoblastoma protein and
cyclin D. J. Biol. Chem. 284, 6175–6184. doi: 10.1074/jbc.M806887200
Zhang, J., Liu, Z. H., Chen, Z. H., Li, Y. J., and Li, L. S. (1999). Effect of rhein on
glucose transporter-1 expression and its function in glomerular mesangial cells.
Chin. Med. J. 112, 1077–1079.
Zhang, Y., Fan, S. J., Hu, N., Gu, M., Chu, C. X., Li, Y. M., et al. (2012).
Rhein reduces fat weight in db/db mouse and prevents diet-induced obesity
in C57Bl/6 mouse through the inhibition of PPAR gamma signaling. PPAR Res.
2012:374936. doi: 10.1155/2012/374936
Zhang, Y., Pizzute, T., and Pei, M. (2014). A review of crosstalk between MAPK
and Wnt signals and its impact on cartilage regeneration. Cell Tissue Res. 358,
633–649. doi: 10.1007/s00441-014-2010-x
Zhao, X. L., Li, J., Zhu, S. F., Liu, Y. L., Zhao, J. L., Wan, M. H., et al. (2014).
Rhein induces a necrosis-apoptosis switch in pancreatic acinar cells. Evid. Based
Complement. Altern. Med. 2014:404853. doi: 10.1155/2014/404853
Zhao, Y. L., Zhou, G. D., Yang, H. B., Wang, J. B., Shan, L. M., Li, R. S., et al. (2011).
Rhein protects against acetaminophen-induced hepatic and renal toxicity. Food
Chem. Toxicol. 49, 1705–1710. doi: 10.1016/j.fct.2011.04.011
Frontiers in Pharmacology | www.frontiersin.org 15 August 2016 | Volume 7 | Article 247
Sun et al. Rhein: A Comprehensive and System Review
Zheng, J. M., Zhu, J. M., Li, L. S., and Liu, Z. H. (2008). Rhein reverses the diabetic
phenotype of mesangial cells over-expressing the glucose transporter (GLUT1)
by inhibiting the hexosamine pathway. Br. J. Pharmacol. 153, 1456–1464. doi:
10.1038/bjp.2008.26
Zhong, X. F., Huang, G. D., Luo, T., Deng, Z. Y., and Hu, J. N. (2012). Protective
effect of rhein against oxidative stress-related endothelial cell injury.Mol. Med.
Rep. 5, 1261–1266. doi: 10.3892/mmr.2012.793
Zhou, J., Du, T., Li, B., Rong, Y., Verkhratsky, A., and Peng, L. (2015).
Crosstalk between MAPK/ERK and PI3K/AKT signal pathways during
brain ischemia/reperfusion. ASN Neuro 7:1759091415602463. doi:
10.1177/1759091415602463
Zhou, Y. X., Xia, W., Yue, W., Peng, C., Rahman, K., and Zhang, H. (2015). Rhein:
a review of pharmacological activities. Evid. Based Complement. Altern. Med.
2015:578107. doi: 10.1155/2015/578107
Zhu, J. M., Liu, Z. H., Huang, H. D., Chen, Z. H., and Li, L. S. (2003). Rhein inhibits
transforming growth factor beta 1 induced plasminogen activator inhibitor-1 in
endothelial cells. Chin. Med. J. 116, 354–359.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Sun, Luo, Chen and Xiang. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 16 August 2016 | Volume 7 | Article 247
